The estimated Net Worth of Rainer M Erdtmann is at least 85.9 千$ dollars as of 16 December 2019. Rainer Erdtmann owns over 31,846 units of PolarityTE Inc stock worth over 7,200$ and over the last 6 years Rainer sold PTE stock worth over 78,660$.
Rainer has made over 2 trades of the PolarityTE Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Rainer sold 31,846 units of PTE stock worth 78,660$ on 16 December 2019.
The largest trade Rainer's ever made was selling 31,846 units of PolarityTE Inc stock on 16 December 2019 worth over 78,660$. On average, Rainer trades about 5,504 units every 65 days since 2018. As of 16 December 2019 Rainer still owns at least 30,000 units of PolarityTE Inc stock.
You can see the complete history of Rainer Erdtmann stock trades at the bottom of the page.
Rainer's mailing address filed with the SEC is C/O SUMMIT THERAPEUTICS INC.,, ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at PolarityTE Inc have traded over 998,958$ worth of PolarityTE Inc stock and bought 381,180 units worth 1,230,731$ . The most active insiders traders include Steve Gorlin、Peter A Cohen、Paul Elliot Mann. On average, PolarityTE Inc executives and independent directors trade stock every 21 days with the average trade being worth of 3,753$. The most recent stock trade was executed by Chris Nolet on 12 January 2023, trading 36,497 units of PTE stock currently worth 8,759$.
polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™
PolarityTE Inc executives and other stock owners filed with the SEC include: